1. Home
  2. EVT vs TSHA Comparison

EVT vs TSHA Comparison

Compare EVT & TSHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Eaton Vance Tax Advantaged Dividend Income Fund of Beneficial Interest

EVT

Eaton Vance Tax Advantaged Dividend Income Fund of Beneficial Interest

HOLD

Current Price

$26.65

Market Cap

1.9B

Sector

Finance

ML Signal

HOLD

Logo Taysha Gene Therapies Inc.

TSHA

Taysha Gene Therapies Inc.

HOLD

Current Price

$6.32

Market Cap

1.8B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
EVT
TSHA
Founded
N/A
2019
Country
United States
United States
Employees
N/A
N/A
Industry
Finance Companies
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.9B
1.8B
IPO Year
2003
2020

Fundamental Metrics

Financial Performance
Metric
EVT
TSHA
Price
$26.65
$6.32
Analyst Decision
Strong Buy
Analyst Count
0
8
Target Price
N/A
$11.63
AVG Volume (30 Days)
106.5K
2.0M
Earning Date
01-01-0001
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
5.56
EPS
N/A
N/A
Revenue
N/A
$9,773,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$1,152.42
P/E Ratio
N/A
N/A
Revenue Growth
N/A
17.28
52 Week Low
$23.00
$2.25
52 Week High
$27.46
$7.30

Technical Indicators

Market Signals
Indicator
EVT
TSHA
Relative Strength Index (RSI) 49.91 62.31
Support Level $25.97 $6.11
Resistance Level $26.72 $6.76
Average True Range (ATR) 0.52 0.40
MACD -0.07 0.09
Stochastic Oscillator 27.91 88.73

Price Performance

Historical Comparison
EVT
TSHA

About EVT Eaton Vance Tax Advantaged Dividend Income Fund of Beneficial Interest

EATON VANCE TAX ADVANTAGED DIVIDEND INCOME FUND is a diversified, closed-end management investment company. Its objective is to provide a high level of after-tax total return consisting mainly of tax-advantaged dividend income and capital appreciation. The fund pursues its objective by investing in dividend-paying common and preferred stocks. Its portfolio of investments consists of electric utilities, energy equipment and services, food products, health care providers and services, internet software and services, and other areas.

About TSHA Taysha Gene Therapies Inc.

Taysha Gene Therapies Inc is a clinical-stage biotechnology company focused on advancing AAV-based gene therapies for the treatment of severe monogenic diseases of the central nervous system, or CNS. The company's clinical program TSHA-102 is in development for the treatment of Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease. The Company views its operations and manages its business as a single operating segment, the gene therapy segment, which is the business of developing AAV-based gene therapies for the treatment of rare monogenic diseases of the central nervous system.

Share on Social Networks: